ImmunoCellular seeks next level leader after CEO resignation 'mess'
This article was originally published in Scrip
ImmunoCellular Therapeutics founder, chief scientific officer and chairman John Yu told Scrip that the Los Angeles-based cancer vaccine developer is "looking for a leader to take the company to the next level" since president and CEO Manish Singh resigned "to pursue other opportunities."
You may also be interested in...
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.